Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan

REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic so...

Descripción completa

Detalles Bibliográficos
Autores principales: Kamata, Kazuhiro, Jindai, Kazuaki, Ichihara, Nao, Saito, Hiroki, Kato, Hideaki, Kunishima, Hiroyuki, Shintani, Ayumi, Nishida, Osamu, Fujitani, Shigeki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046264/
https://www.ncbi.nlm.nih.gov/pubmed/33853684
http://dx.doi.org/10.1186/s40560-021-00547-7
_version_ 1783678815682166784
author Kamata, Kazuhiro
Jindai, Kazuaki
Ichihara, Nao
Saito, Hiroki
Kato, Hideaki
Kunishima, Hiroyuki
Shintani, Ayumi
Nishida, Osamu
Fujitani, Shigeki
author_facet Kamata, Kazuhiro
Jindai, Kazuaki
Ichihara, Nao
Saito, Hiroki
Kato, Hideaki
Kunishima, Hiroyuki
Shintani, Ayumi
Nishida, Osamu
Fujitani, Shigeki
author_sort Kamata, Kazuhiro
collection PubMed
description REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies.
format Online
Article
Text
id pubmed-8046264
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-80462642021-04-15 Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan Kamata, Kazuhiro Jindai, Kazuaki Ichihara, Nao Saito, Hiroki Kato, Hideaki Kunishima, Hiroyuki Shintani, Ayumi Nishida, Osamu Fujitani, Shigeki J Intensive Care Letter to the Editor REMAP-CAP, a randomized, embedded, multifactorial adaptive platform trial for community-acquired pneumonia, is an international clinical trial that is rapidly expanding its scope and scale in response to the COVID-19 pandemic. Japan is now joining REMAP-CAP with endorsement from Japanese academic societies. Commitment to REMAP-CAP can significantly contribute to population health through timely identification of optimal COVID-19 therapeutics. Additionally, it will promote the establishment of a national and global network of clinical trials to tackle future pandemics of emerging and re-emerging infectious diseases, in collaboration with multiple stakeholders, including front-line healthcare workers, governmental agencies, regulatory authorities, and academic societies. BioMed Central 2021-04-14 /pmc/articles/PMC8046264/ /pubmed/33853684 http://dx.doi.org/10.1186/s40560-021-00547-7 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter to the Editor
Kamata, Kazuhiro
Jindai, Kazuaki
Ichihara, Nao
Saito, Hiroki
Kato, Hideaki
Kunishima, Hiroyuki
Shintani, Ayumi
Nishida, Osamu
Fujitani, Shigeki
Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
title Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
title_full Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
title_fullStr Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
title_full_unstemmed Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
title_short Why participation in an international clinical trial platform matters during a pandemic? Launching REMAP-CAP in Japan
title_sort why participation in an international clinical trial platform matters during a pandemic? launching remap-cap in japan
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8046264/
https://www.ncbi.nlm.nih.gov/pubmed/33853684
http://dx.doi.org/10.1186/s40560-021-00547-7
work_keys_str_mv AT kamatakazuhiro whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT jindaikazuaki whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT ichiharanao whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT saitohiroki whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT katohideaki whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT kunishimahiroyuki whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT shintaniayumi whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT nishidaosamu whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan
AT fujitanishigeki whyparticipationinaninternationalclinicaltrialplatformmattersduringapandemiclaunchingremapcapinjapan

Ejemplares similares